Lepton PharmaceuticalsLepton Pharmaceuticals
 
Lepton PharmaceuticalsLepton Pharmaceuticals
  • Home
  • About Us
    • About Us
    • Board of directors
    • Team
  • Our Products
    • Pipeline
    • LN-Cast-01
    • LN-008 si-MASP2
  • Our Science
    • miRNA based Castling
    • siRNA and miRNA
    • Non-coding RNA
    • siRNA Advantages
  • Contact Us
  • News

PRODUCTSDon’t worry, we have it

Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward.
bt_bb_section_bottom_section_coverage_image

Recent Posts

  • August 23, 2023Lepton Announced Completion of Filing for a Patent Application Extending the Usage of Its Castling Breakthrough Technologies

  • July 13, 2023Lepton Pharmaceuticals Completed the Extension Worldwide of its International Patent Covering the Breakthrough Castling Technology

  • March 20, 2023Lepton Pharmaceuticals enter into a Master Service Agreement with Reaction Biology to advance Lepton’s miRNA Castling Technology

  • July 26, 2022ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

  • February 14, 2022Lepton signs Consulting Agreement with Cell Therapy Expert Dr. Elena Sotillo, Senior Research Scientist at the lab of Prof. Crystal Mackall founding director, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, Ca, USA

https://www.leptonpharma.com/wp-content/uploads/2021/04/logo_white_big-160x160.png

© 2023 Lepton Pharmaceuticals Inc.  All rights reserved
Design & Development by WCT

Our products

  • LN-Cast-01
  • LN-008 siMASP2

Our science

  • Castling Technology
  • siRNA and miRNA
  • Non-coding RNA
  • siRNA Advantages

Terms of use

  • Terms of Use
  • Copyright Info
  • Privacy Policy